Piper Sandler analyst Yasmeen Rahimi initiated coverage of Tenax Therapeutics (TENX) with an Overweight rating and $20 price target The company is s developing TNX-103 in pulmonary hypertension associated with heart failure with preserved ejection fraction with the Phase 3 LEVEL readout expected in the second half of 2026, the analyst tells investors in a research note. The firm believes Tenax is “flying under the radar” despite having the potential win approval in a high unmet need indication.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX: